Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of CBP-0276 200mg/Day Twice Dose a Day, or Placebo Administrated for 36 Weeks, to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects 18y to 70y: Randomized Controlled Trial

NCT07204639 is registered in ClinicalTrials.gov with Clarent Biopharma, Inc. as lead sponsor.

NCT NCT07204639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07204639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of CBP-0276 200mg/Day Twice Dose a Day, or Placebo Administrated for 36 Weeks, to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects 18y to 70y: Randomized Controlled Trial
Lead sponsor
Clarent Biopharma, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
October 1, 2025
Completion date
August 30, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis